Integrated Telecommunication Services

The Dow Jones extended gains later during the session, adding more than 150 points on Wednesday. Alphabet Inc. (NASDAQ: GOOGL) reported upbeat results for its fourth quarter and also announced a 20-for-1 stock split. Toward the end of trading Wednesday, the Dow traded up 0.45% to 35,563.95 while...

US stocks pared earlier gains, with the Nasdaq Composite turning lower on Wednesday. Alphabet Inc. (NASDAQ: GOOGL) reported upbeat results for its fourth quarter and also announced a 20-for-1 stock split. Midway through trading Wednesday, the Dow traded up 0.10% to 35,439.05 while the NASDAQ...

Gainers MDJM Ltd (NASDAQ: MDJH) jumped 27.2% to $2.29 after gaining 10% on Tuesday. Allegheny Technologies Incorporated (NYSE: ATI) gained 14.3% to $21.50 after the company posted upbeat Q4 results and announced a $150 million buyback plan. Epizyme, Inc. (NASDAQ: EPZM) rose 12.6% to $1.3850....

Dynatrace Inc (NYSE: DT) reported third-quarter FY22 revenue growth of 32% year-on-year to $240.8 million, beating the consensus of $234.4 million.  Total ARR increased 29% Y/Y to $930 million. Revenues from Subscription rose 33% Y/Y to $226 million. Margins: The non-GAAP...

Keybanc cut the price target on The Sherwin-Williams Company (NYSE: SHW) from $394 to $335. Sherwin-Williams shares rose 1.6% to close at $287.70 on Friday. JP Morgan cut V.F. Corporation (NYSE: VFC) price target from $80 to $64. V.F. Corporation shares fell 1.8% to $61.83 in pre-market...

UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading. SVB Leerink lowered the price target on Equillium, Inc. (NASDAQ: EQ) from $18 to $14. Equillium shares gained 2.2% to $3.68 in pre-market trading. Wells Fargo cut...

Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-...

Equillium Inc's (NASDAQ: EQ) Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective. The data demonstrated an on-target peak and sustained reduction of CD6 at Day 85 (one month following the last dose).  The data, collected from a total...

Equillium Inc (NASDAQ: EQ) announced interim data from the Type A portion of the Phase 1b EQUALISE study in systemic lupus erythematosus (SLE) patients. Data were presented at the American College of Rheumatology (ACR) annual meeting.  The data showed that itolizumab...

Dynatrace Inc (NYSE: DT) reported second-quarter FY22 revenue growth of 34% year-on-year to $226.4 million, beating the consensus of $220.6 million.  Total ARR increased 35% Y/Y to $864 million. Revenues from Subscription rose 35% Y/Y to $212.6 million. Margins: The non-...

Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value of $2.26 billion. Vivos Therapeutics, Inc. (NASDAQ: VVOS) rose 53.7% to settle at $5.90. The FDA...

Dynatrace Inc (NYSE: DT) reported first-quarter FY22 revenue growth of 35% year-on-year to $209.7 million, beating the analyst consensus of $203.4 million. Total ARR increased 37% Y/Y to $823 million. The unique value of combining the broadest cloud observability with powerful...

Equillium Inc (NASDAQ: EQ) completed an End-of-Phase 1 meeting with the FDA, confirming to advance itolizumab into a single Phase 3 pivotal study in first-line treatment of acute graft-versus-host disease (aGVHD) patients. The company plans to initiate the Phase 3 study in 4Q of...

Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares gained 62.4% to settle at $14.68 after the company reported the B-SIMPLE4 pivotal Phase 3 trial of SB206 achieved statistical...

Equillium Inc (NASDAQ: EQ) has announced positive topline data from the Phase 1b EQUATE study evaluating itolizumab in first-line acute graft-versus-host-disease (aGVHD). The results were presented at the European Hematology Association 2021 Virtual Congress. All patients in the...